Reports Q2 revenue $87M, consensus $69.34M. “We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We were especially pleased with the substantial top-line growth as well as growth in test report volumes across our therapeutic areas.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- CSTL Earnings this Week: How Will it Perform?
- Canaccord recommends buying Castle Biosciences on weakness after MolDX news
- Castle MolDX update doesn’t impact current Dx-SCC Medicare coverage, says Baird
- Castle Biosciences downside risk ‘limited’ on MolDx decision, says Leerink
- Castle Biosciences slides after MolDX determination on carcinoma test